Literature DB >> 20948308

Life or death: p53-induced apoptosis requires DNA binding cooperativity.

Katharina Schlereth1, Joël P Charles, Anne C Bretz, Thorsten Stiewe.   

Abstract

The tumor suppressor p53 provides exquisite protection from cancer by balancing cell survival and death in response to stress. Sustained stress or irreparable damage trigger p53's killer functions to permanently eliminate genetically-altered cells as a potential source of cancer. To prevent the unnecessary loss of cells that could cause premature aging as a result of stem cell attrition, the killer functions of p53 are tightly regulated and balanced against protector functions that promote damage repair and support survival in response to low stress or mild damage. In molecular terms these p53-based cell fate decisions involve protein interactions with cofactors and modifying enzymes, which modulate the activation of distinct sets of p53 target genes. In addition, we demonstrate that part of this regulation occurs at the level of DNA binding. We show that the killer function of p53 requires the four DNA binding domains within the p53 tetramer to interact with one another. These intermolecular interactions enable cooperative binding of p53 to less perfect response elements in the genome, which are present in many target genes essential for apoptosis. Modulating p53 interactions within the tetramer could therefore present a novel promising strategy to fine-tune p53-based cell fate decisions.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20948308      PMCID: PMC3055192          DOI: 10.4161/cc.9.20.13595

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  72 in total

1.  Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.

Authors:  C Perez-Sanchez; V S Budhram-Mahadeo; D S Latchman
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

2.  Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53.

Authors:  Woojin An; Jaehoon Kim; Robert G Roeder
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

3.  Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs.

Authors:  Simon Cawley; Stefan Bekiranov; Huck H Ng; Philipp Kapranov; Edward A Sekinger; Dione Kampa; Antonio Piccolboni; Victor Sementchenko; Jill Cheng; Alan J Williams; Raymond Wheeler; Brant Wong; Jorg Drenkow; Mark Yamanaka; Sandeep Patel; Shane Brubaker; Hari Tammana; Gregg Helt; Kevin Struhl; Thomas R Gingeras
Journal:  Cell       Date:  2004-02-20       Impact factor: 41.582

4.  Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators.

Authors:  Jamie M Hearnes; Deborah J Mays; Kristy L Schavolt; Luojia Tang; Xin Jiang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

5.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

6.  Hzf, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage.

Authors:  Masataka Sugimoto; Adam Gromley; Charles J Sherr
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

7.  Negative regulation of the mammalian UV response by Myc through association with Miz-1.

Authors:  Steffi Herold; Michael Wanzel; Vincent Beuger; Carsten Frohme; Dorothee Beul; Tomi Hillukkala; Juhani Syvaoja; Hans-Peter Saluz; Frank Haenel; Martin Eilers
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

8.  Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.

Authors:  T Frebourg; J Kassel; K T Lam; M A Gryka; N Barbier; T I Andersen; A L Børresen; S H Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

9.  Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter.

Authors:  Raphaël Métivier; Graziella Penot; Michael R Hübner; George Reid; Heike Brand; Martin Kos; Frank Gannon
Journal:  Cell       Date:  2003-12-12       Impact factor: 41.582

10.  iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.

Authors:  Daniele Bergamaschi; Yardena Samuels; Nigel J O'Neil; Giuseppe Trigiante; Tim Crook; Jung-Kuang Hsieh; Daniel J O'Connor; Shan Zhong; Isabelle Campargue; Matthew L Tomlinson; Patricia E Kuwabara; Xin Lu
Journal:  Nat Genet       Date:  2003-01-13       Impact factor: 38.330

View more
  24 in total

Review 1.  Senescence and apoptosis: dueling or complementary cell fates?

Authors:  Bennett G Childs; Darren J Baker; James L Kirkland; Judith Campisi; Jan M van Deursen
Journal:  EMBO Rep       Date:  2014-10-13       Impact factor: 8.807

2.  Pro-metastatic p53 mutants control folding of N-glycoproteins.

Authors:  Jean Schneikert; Thorsten Stiewe
Journal:  Cell Cycle       Date:  2017-02-06       Impact factor: 4.534

3.  p53 functions in endothelial cells to prevent radiation-induced myocardial injury in mice.

Authors:  Chang-Lung Lee; Everett J Moding; Kyle C Cuneo; Yifan Li; Julie M Sullivan; Lan Mao; Iman Washington; Laura B Jeffords; Rafaela C Rodrigues; Yan Ma; Shiva Das; Christopher D Kontos; Yongbaek Kim; Howard A Rockman; David G Kirsch
Journal:  Sci Signal       Date:  2012-07-24       Impact factor: 8.192

4.  Distinct p53 genomic binding patterns in normal and cancer-derived human cells.

Authors:  Krassimira Botcheva; Sean R McCorkle; W R McCombie; John J Dunn; Carl W Anderson
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

5.  Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Authors:  Ellen Weisberg; Ensar Halilovic; Vesselina G Cooke; Atsushi Nonami; Tao Ren; Takaomi Sanda; Irene Simkin; Jing Yuan; Brandon Antonakos; Louise Barys; Moriko Ito; Richard Stone; Ilene Galinsky; Kristen Cowens; Erik Nelson; Martin Sattler; Sebastien Jeay; Jens U Wuerthner; Sean M McDonough; Marion Wiesmann; James D Griffin
Journal:  Mol Cancer Ther       Date:  2015-07-23       Impact factor: 6.261

6.  Rap2b, a novel p53 target, regulates p53-mediated pro-survival function.

Authors:  Xinyue Zhang; Yunlong He; Kyoung-Hwa Lee; Wendy Dubois; Ziqing Li; Xiaolin Wu; Alexander Kovalchuk; Weimin Zhang; Jing Huang
Journal:  Cell Cycle       Date:  2013-03-27       Impact factor: 4.534

7.  Role of p53 in regulating tissue response to radiation by mechanisms independent of apoptosis.

Authors:  Chang-Lung Lee; Jordan M Blum; David G Kirsch
Journal:  Transl Cancer Res       Date:  2013-10       Impact factor: 1.241

Review 8.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

9.  Inactivation of Mdm2 restores apoptosis proficiency of cooperativity mutant p53 in vivo.

Authors:  Boris Klimovich; Thorsten Stiewe; Oleg Timofeev
Journal:  Cell Cycle       Date:  2019-11-21       Impact factor: 4.534

10.  Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling.

Authors:  Franziska Wachter; Michaela Grunert; Cristina Blaj; David M Weinstock; Irmela Jeremias; Harald Ehrhardt
Journal:  Cell Commun Signal       Date:  2013-04-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.